Thomas Struengmann & family
$10.66B
$65.8M (0.6%)
as of 11/07/24
About Thomas Struengmann & family
Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.
The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
Personal stats
Citizenship
GermanySource of wealth
PharmaceuticalsResidence
Tegernsee, GermanyMarital status
MarriedBirth date
02/16/50 (age 74)Number of children
4Education
Master of Business Administration, University of Augsburg; Master of Business Administration, University of AugsburgSelf-made
self-madeThomas Struengmann & family’s fortune is worth
178K
troy ounces of gold
164K
median U.S. household
107K
median U.S. income
0.213%
U.S. credit card volume
0.043%
GDP of the United States
0.031%
United States debt
Net worth history
Annual ranking
Did you know?
Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | BNTX-US
BioNTech Sponsored ADRundefined | undefined
FormyconImages © Forbes.com. All rights reserved.